Compare Pfizer Inc (PFE) vs Zillow Group Inc Class C (Z) Price & Performance

Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.

The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.

Zillow Group (Z) trades at $27.28, down 1.52% on the day, with technical indicators signaling a bearish trend amid weak moving averages. The company reported revenue of $2.58 billion in 2025, with net income turning positive at $23 million, and recent quarters show mixed earnings performance with two beats and one miss. Analyst sentiment is divided, with a consensus price target of $60.33, while news highlights focus on market competition and AI integration in real estate.

The stock faces headwinds from a challenging housing market and high valuation multiples, but long-term growth potential exists through its transaction platform expansion and AI initiatives. Risks include interest rate sensitivity and competitive pressures, yet institutional analyst coverage remains largely neutral to positive, suggesting cautious optimism for recovery if execution improves.